Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma (Q35023508)

5 August 2017

title

Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma (English)

1 reference

5 August 2017

1 reference

1 reference

1 reference

4

Corey J Langer

1 reference

5 August 2017

Girum L Lemma

1

1 reference

5 August 2017

Ju-Whei Lee

2

1 reference

5 August 2017

Seena C Aisner

3

1 reference

5 August 2017

William J Tester

5

1 reference

5 August 2017

David H Johnson

6

1 reference

5 August 2017

Patrick J Loehrer

7

1 reference

5 August 2017

language of work or name

English

0 references

publication date

18 April 2011

1 reference

Journal of Clinical Oncology

5 August 2017

published in

1 reference

5 August 2017

volume

29

1 reference

5 August 2017

issue

15

1 reference

5 August 2017

page(s)

2060-2065

1 reference

Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107762

Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107762

Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107762

Thymoma, atypical thymoma, and thymic carcinoma. A novel conceptual approach to the classification of thymic epithelial neoplasms

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107762

Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107762

EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107762

Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107762

Follow-up study of thymomas with special reference to their clinical stages

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107762

The spectrum of diseases associated with thymoma. Coincidence or syndrome?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107762

Primary anterior mediastinal tumors in children and adults

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107762

Thymoma--report of 71 cases and a review

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107762

Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107762

Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107762

A case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapy.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107762

Treatment of invasive thymoma with single-agent ifosfamide

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107762

Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan

25 October 2018

1 reference

12 December 2020

J. Maxwell Chamberlain Memorial Paper. Role of staging in prognosis and management of thymoma

1 reference

12 December 2020

Chemotherapy for invasive thymoma. A 13-year experience

1 reference

12 December 2020

Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma

1 reference

12 December 2020

Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

12 December 2020

A novel second line chemotherapy treatment of recurrent thymoma

1 reference

12 December 2020

Mediastinal masses: diagnostic approach

1 reference

12 December 2020

Persistent and aggressive treatment for thymic carcinoma. Results of a single-institute experience with 25 patients

1 reference

12 December 2020

Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2010.32.9607

1 reference

5 August 2017

1 reference

5 August 2017

1 reference